NCT07152782 2025-09-03
THUNDER
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07019272 2025-06-13
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Not yet recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06519110 2024-07-25
CVL009-C2001
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT06374888 2024-04-19
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT05491057 2022-08-08
Treatment Patterns of Neratinib in HER2+ EBC in China
Pierre Fabre Medicament
Not yet recruiting